X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): INDV-1000
Therapeutic Area: Psychiatry/Psychology Product Name: INDV-1000
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Indivior
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 29, 2021
Details:
INDV-1000 is a selective GABAb positive allosteric modulator for alcohol use disorder. The new funding will be used to prepare drug candidates for both Indivior’s substance use disorder program and Addex’s proprietary Charcot-Marie-Tooth type 1A neuropathy program.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SYT-510
Therapeutic Area: Psychiatry/Psychology Product Name: SYT-510
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Ysios Capital
Deal Size: $26.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 20, 2021
Details:
This investment brings total Series A financing to CHF 24 million to complete pre-clinical development and progress lead candidate through proof-of-concept clinical studies. Synendos is advancing the preclinical and clinical development of SYT-510.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
